Navigation Links
Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
Date:2/15/2011

IRVINE, Calif., Feb. 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the presentation of the initial clinical results from the PEVAR Trial at the 2011 iCON (International Congress of Endovascular Specialists) annual meeting in Scottsdale, Arizona. Among 33 patients enrolled in the Roll-In phase of the trial, technical success rates of 97% (access) and 100% (endovascular repair) have been achieved, with no major adverse events observed. Patients were discharged from the hospital at an average of 1.4 days following the procedure.

Participating investigator and presenter Zvonimir Krajcer, MD (Director, Peripheral Vascular Disease Service, St. Luke's Episcopal Hospital at the Texas Heart Institute, Houston, TX) commented, "In our multidisciplinary practice, a totally percutaneous approach to endovascular repair with the IntuiTrak System and Abbott's Prostar XL closure device has demonstrated substantial patient benefits as we recently reported in the Journal of Cardiovascular Surgery.   These initial outcomes in the PEVAR Trial roll-in phase are consistent with the published single center data, and have served to support initiation of the randomized phase of the trial. We are very pleased with the initial results, and look forward to completion of the randomized trial very soon."

The PEVAR Trial is the first multicenter, prospective, randomized trial of totally percutaneous endovascular repair of abdominal aortic aneurysm and is being conducted at 20 centers in the United States under an Investigational Device Exemption approved by the U.S. Food and Drug Administration.

John McDermott, President and Chief Executive Officer said, "We applaud the PEVAR Trial investigators for their diligence and dedication to the trial, and commitment to improving patient outcomes. We are encouraged by the initial trial results, and look forward to completion of this trial in the near future."

About iCONThe International Congress for Endovascular Specialists annual meeting is presented by the Arizona Heart Foundation and the International Society of Endovascular Specialists.  The meeting provides a multidisciplinary forum for the discussion of a wide range of endovascular topics including acute stroke, carotid artery disease, structural heart disease, heart failure therapies, thoracic and abdominal aortic pathologies, and peripheral vascular disorders. There are also concurrent cardiac sessions addressing chronic heart failure, arrhythmias, and percutaneous valve replacement.  The meeting is being held from February 13-17, 2011 in Scottsdale, Arizona.  More information is available at www.iconmeeting.org.  

About Endologix, Inc.Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA).  AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.COMPANY CONTACT:

INVESTOR CONTACTS:Endologix, Inc.

The Ruth GroupJohn McDermott, CEO

Nick Laudico (646) 536-7030(949) 595-7200

Zack Kubow (646) 536-7020www.endologix.com
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
6. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
7. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
8. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
9. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
10. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
11. Endologix Reports 30% Third Quarter 2010 Revenue Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced that it will release fourth quarter and ... March 2nd, 2017. AcelRx management will host an ... (1:30 p.m. Pacific Time) on March 2 nd ...
(Date:2/23/2017)... COTTAGE, New York , February 23, 2017 /PRNewswire/ ... health implications arising from increasing caseload for varicose veins ... recorded across the globe are prompting the adoption of ... latest study on global endovenous laser therapy ... attention towards aftereffects of lifestyle choices and consequences of ...
(Date:2/23/2017)... Research and Markets has announced the addition ... Forecast to 2025" report to their offering. ... The Global Endoscopy Market is ... next decade to reach approximately $47.6 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
(Date:2/23/2017)... Lawn, NJ (PRWEB) , ... February 23, 2017 ... ... specializing in thought leadership , media relations, content marketing, social media management, ... With several clients already in the state and in nearby New Hampshire, Massachusetts ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... interactive publication where generations converge and explore the world from different perspectives. By ... Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation , a ... franchising throughout the U.S. starting this spring. Current Meditation focuses on “meditation for ... mainstream. Current Meditation will be the first meditation concept in the U.S. offering ...
Breaking Medicine News(10 mins):